Santhera Pharmaceuticals Reports Preliminary Unaudited Revenues for the Year 2017; Provides Earnings Guidance for the Year 2017 and Sales Guidance for the Year 2018
For 2017, the company anticipates a net loss of CHF 50 million to CHF 55 million.
For 2018, the company expects net sales of Raxone for the currently approved indication LHON to reach CHF 28 to 30 million.